Session Detail


Session Title: Novel Immune and Targeted Therapies for Hematologic Malignancies and Solid Tumors
Session Type: Clinical Trials Symposium
Session Start/End Time: Sunday, Apr 06, 2014, 3:15 PM - 5:15 PM
Location: Ballroom 20A-C, San Diego Convention Center
CME: CME-Designated
CME/CE Hours: 2
Presentations:
Chairperson
Sunday, Apr 06, 2014, 3:15 PM - 5:00 PM
Joseph Paul Eder. Yale University, New Haven, CT
CT102: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Sunday, Apr 06, 2014, 3:15 PM - 3:35 PM
Michel Sadelain, Renier Brentjens, Marco Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Diana Bouhassira, Kevin Curran, Stephen Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Sergio Giralt. Mem. Sloan-Kettering Cancer Ctr., New York, NY, Mem. Sloan-Kettering Cancer Ctr., New York, NY
Discussant
Sunday, Apr 06, 2014, 3:35 PM - 3:45 PM
Carl H. June. Abramson Cancer Ctr. of Univ. of Penn., Philadelphia, PA
CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
Sunday, Apr 06, 2014, 3:45 PM - 4:05 PM
Eytan Stein, Martin Tallman, Daniel A. Pollyea, Ian W. Flinn, Amir T. Fathi, Richard M. Stone, Ross L. Levine, Samuel Agresta, David Schenkein, Hua Yang, Bin Fan, Kate Yen, Stephane De Botton. Memorial Sloan-Kettering Cancer Center, New York, NY, University of Colorado Cancer Center, Aurora, CO, Sarah Cannon Research Institute, Nashville, TN, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute, Boston, MA, Agios Pharmaceuticals, Cambridge, MA, Institut Gustave Roussy, Villejuif, France
Discussant
Sunday, Apr 06, 2014, 4:05 PM - 4:15 PM
John C. Byrd. Ohio State Univ. Comp. Cancer Ctr., Columbus, OH
CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome
Sunday, Apr 06, 2014, 4:15 PM - 4:35 PM
Adil I. Daud1, Omid Hamid2, Antoni Ribas3, F. Stephen Hodi4, Wen-Jen Hwu5, Richard Kefford6, Jedd Wolchok7, Peter Hersey6, Jeffrey S. Weber8, Richard Joseph9, Tara C. Gangadhar10, Roxana S. Dronca11, Amita Patnaik12, Hassane Zarour13, Anthony M. Joshua14, Kevin Gergich15, Dianna Wu15, Jared K. Lunceford16, Kenneth Emancipator16, Marisa Dolled-Filhart16, Nicole Li15, Scot Ebbinghaus15, S. Peter Kang17, Caroline Robert18. 1UCSF School of Medicine, San Francisco, CA; 2The Angeles Clinic and Research Institute, Los Angeles, CA; 3David Geffen UCLA School of Medicine, Los Angeles, CA; 4Dana-Farber Cancer Institute, Boston, MA; 5The University of Texas MD Anderson Cancer Center, Houston, TX; 6University of Sydney, Sydney, Australia; 7Memorial Sloan-Kettering Cancer Center, New York, NY; 8H. Lee Moffitt Cancer Center, Tampa, FL; 9Mayo Clinic Cancer Center, Jacksonville, FL; 10Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; 11Mayo Clinic, Rochester, MN; 12South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 13University of Pittsburgh, Pittsburgh, PA; 14Princess Margaret Cancer Centre, Toronto, ON, Canada; 15Merck, North Wales, PA; 16Merck, Rahway, NJ; 17Merck Research Laboratories, Kenilworth, NJ; 18Gustave Roussy, Villejuif, France
CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
Sunday, Apr 06, 2014, 4:35 PM - 4:55 PM
Leena Gandhi1, Ani Balmanoukian2, Rina Hui3, Omid Hamid2, Naiyer A. Rizvi4, Natasha Leighl5, Matthew Gubens6, Jonathan W. Goldman7, Gregory M. Lubiniecki8, Kenneth Emancipator9, Marisa Dolled-Filhart9, Jared K. Lunceford9, Michelle Niewood10, Kevin Gergich8, Edward B. Garon11. 1Dana-Farber Cancer Institute, Boston, MA; 2The Angeles Clinic and Research Institute, Los Angeles, CA; 3Westmead Hospital, Sydney, Australia; 4Memorial Sloan-Kettering Cancer Center, New York, NY; 5Princess Margaret Hospital, Toronto, ON, Canada; 6University of California, San Francisco, San Francisco, CA; 7UCLA, Santa Monica, CA; 8Merck & Co., Inc., North Wales, PA; 9Merck & Co., Inc., Rahway, NJ; 10Merck & Co., Inc., Philadelphia, PA; 11David Geffen School of Medicine at UCLA, Los Angeles, CA
Discussant
Sunday, Apr 06, 2014, 4:55 PM - 5:15 PM
Mario Sznol. Yale Cancer Ctr., New Haven, CT